Elenbecestat trials to be discontinued for early Alzheimer’s disease: industry news round-up

Written by Sharon Salt, Editor

This week in industry we’re covering some of the biggest stories that have made the headlines, including the decision to discontinue the elenbecestat trials for Alzheimer’s disease and Toca 511/Toca FC failing to meet their primary endpoint for high-grade glioma. In addition to this, Novartis (Basel, Switzerland) have presented their findings from an earlier report where they indicated that ofatumumab is superior to Aubagio® for relapsing multiple sclerosis (MS). Discover more about our selection of this week’s highlights below (click to navigate): Elenbecestat trials to be discontinued for early Alzheimer’s disease Ofatumumab is superior to Aubagio for relapsing multiple sclerosis...

To view the full article, please register now for access

It's completely free